Immutep Limited (IMM.AX)
AUD 0.24
(4.44%)
AUD 0.24
(4.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 42.87 Million AUD | 26.07% |
| 2021 | 34 Million AUD | 73.01% |
| 2020 | 19.65 Million AUD | -12.87% |
| 2019 | 22.55 Million AUD | 18.09% |
| 2018 | 19.1 Million AUD | 28.91% |
| 2017 | 14.81 Million AUD | 56.68% |
| 2016 | 9.45 Million AUD | -84.72% |
| 2015 | 61.91 Million AUD | 321.72% |
| 2014 | 14.68 Million AUD | 1.6% |
| 2013 | 14.44 Million AUD | -17.25% |
| 2012 | 17.46 Million AUD | -22.92% |
| 2011 | 22.65 Million AUD | 49.08% |
| 2010 | 15.19 Million AUD | 81.07% |
| 2009 | 8.39 Million AUD | 252.03% |
| 2008 | 2.38 Million AUD | 23.23% |
| 2007 | 1.93 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 Q2 | 22.17 Million AUD | 0.0% |
| 2022 Q4 | 20.9 Million AUD | 0.0% |
| 2022 FY | 42.87 Million AUD | 26.07% |
| 2021 FY | 34 Million AUD | 73.01% |
| 2021 Q2 | 17.97 Million AUD | 0.0% |
| 2021 Q4 | 18.5 Million AUD | 0.0% |
| 2020 FY | 19.65 Million AUD | -12.87% |
| 2020 Q4 | 9.89 Million AUD | 0.0% |
| 2020 Q2 | 11.55 Million AUD | 0.0% |
| 2019 Q2 | 14.98 Million AUD | 0.0% |
| 2019 FY | 22.55 Million AUD | 18.09% |
| 2019 Q4 | 11.74 Million AUD | 0.0% |
| 2018 Q4 | 12.12 Million AUD | 0.0% |
| 2018 Q2 | 3.57 Million AUD | 0.0% |
| 2018 FY | 19.1 Million AUD | 28.91% |
| 2017 FY | 14.81 Million AUD | 56.68% |
| 2017 Q4 | 5.83 Million AUD | 0.0% |
| 2017 Q2 | 3.95 Million AUD | 0.0% |
| 2016 Q3 | 1.78 Million AUD | -49.94% |
| 2016 Q4 | 3.57 Million AUD | 100.65% |
| 2016 FY | 9.45 Million AUD | -84.72% |
| 2016 Q2 | 3.55 Million AUD | 0.0% |
| 2015 FY | 61.91 Million AUD | 321.72% |
| 2015 Q4 | 3.66 Million AUD | 38.47% |
| 2015 Q3 | 2.64 Million AUD | -95.09% |
| 2015 Q2 | 53.99 Million AUD | 0.0% |
| 2014 Q2 | 2.67 Million AUD | 0.0% |
| 2014 FY | 14.68 Million AUD | 1.6% |
| 2014 Q4 | 22.19 Million AUD | 0.0% |
| 2013 Q2 | 1.94 Million AUD | 0.0% |
| 2013 FY | 14.44 Million AUD | -17.25% |
| 2013 Q4 | 2.18 Million AUD | 0.0% |
| 2012 FY | 17.46 Million AUD | -22.92% |
| 2012 Q4 | 958.02 Thousand AUD | 0.0% |
| 2012 Q2 | 2.76 Million AUD | 0.0% |
| 2011 FY | 22.65 Million AUD | 49.08% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | 15.19 Million AUD | 81.07% |
| 2009 FY | 8.39 Million AUD | 252.03% |
| 2008 FY | 2.38 Million AUD | 23.23% |
| 2007 FY | 1.93 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | -533.358% |
| Acrux Limited | 8.55 Million AUD | -401.464% |
| Actinogen Medical Limited | 22.77 Million AUD | -88.293% |
| AnteoTech Limited | 12.18 Million AUD | -251.811% |
| Argenica Therapeutics Limited | 8.26 Million AUD | -418.497% |
| Arovella Therapeutics Limited | 10.78 Million AUD | -297.534% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -5936.917% |
| Alterity Therapeutics Limited | 23.4 Million AUD | -83.175% |
| Amplia Therapeutics Limited | 8.43 Million AUD | -408.258% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -843.267% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -1452.879% |
| Biome Australia Limited | 7.91 Million AUD | -441.954% |
| Biotron Limited | 5.11 Million AUD | -738.934% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -7024.258% |
| BTC Health Limited | -1.03 Million AUD | 4226.874% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | -116.899% |
| CSL Limited | 7.56 Billion AUD | 99.433% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 23.855% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | -36.994% |
| Cynata Therapeutics Limited | 11.12 Million AUD | -285.445% |
| Dimerix Limited | 25.64 Million AUD | -67.199% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | -8.341% |
| Hexima Limited | 1 Million AUD | -4150.33% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -939.309% |
| Immuron Limited | 9.13 Million AUD | -369.201% |
| Imugene Limited | 135.09 Million AUD | 68.262% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -1181.432% |
| Memphasys Limited | 3.67 Million AUD | -1065.6% |
| Nanollose Limited | 12.5 Thousand AUD | -342874.226% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | -31.129% |
| Noxopharm Limited | 7 Million AUD | -512.486% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -2081.699% |
| Nyrada Inc. | 4.55 Million AUD | -841.243% |
| Orthocell Limited | 15.36 Million AUD | -178.962% |
| PharmAust Limited | 6.65 Million AUD | -544.063% |
| Patrys Limited | 4.93 Million AUD | -769.096% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 34.143% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -4705.867% |
| Prescient Therapeutics Limited | 10.89 Million AUD | -293.394% |
| PYC Therapeutics Limited | 60.91 Million AUD | 29.616% |
| Race Oncology Limited | 14.77 Million AUD | -190.276% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -14228.608% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | -97.723% |
| Starpharma Holdings Limited | 22.81 Million AUD | -87.917% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 84.077% |
| Tissue Repair Ltd | 6.66 Million AUD | -543.114% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -620.772% |